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Abstract
Background: In preimplantation mammalian development the transcription factor Sox2 (SRY-related HMG-box gene 2)
forms a complex with Oct4 and functions in maintenance of self-renewal of the pluripotent inner cell mass (ICM). Previously
it was shown that Sox22/2 embryos die soon after implantation. However, maternal Sox2 transcripts may mask an earlier
phenotype. We investigated whether Sox2 is involved in controlling cell fate decisions at an earlier stage.
Methods and Findings: We addressed the question of an earlier role for Sox2 using RNAi, which removes both maternal and
embryonic Sox2 mRNA present during the preimplantation period. By depleting both maternal and embryonic Sox2 mRNA at
the 2-cell stage and monitoring embryo development in vitro we show that, in the absence of Sox2, embryos arrest at the
morula stage and fail to form trophectoderm (TE) or cavitate. Following knock-down of Sox2 via three different short interfering
RNA (siRNA) constructs in 2-cell stage mouse embryos, we have shown that the majority of embryos (76%) arrest at the morula
stage or slightly earlier and only 18.7–21% form blastocysts compared to 76.2–83% in control groups. In Sox2 siRNA-treated
embryos expression of pluripotency associated markers Oct4 and Nanog remained unaffected, whereas TE associated markers
Tead4, Yap, Cdx2, Eomes, Fgfr2, as well as Fgf4, were downregulated in the absence of Sox2. Apoptosis was also increased in
Sox2 knock-down embryos. Rescue experiments using cell-permeant Sox2 protein resulted in increased blastocyst formation
from 18.7% to 62.6% and restoration of Sox2, Oct4, Cdx2 and Yap protein levels in the rescued Sox2-siRNA blastocysts.
Conclusion and Significance: We conclude that the first essential function of Sox2 in the preimplantation mouse embryo is
to facilitate establishment of the trophectoderm lineage. Our findings provide a novel insight into the first differentiation
event within the preimplantation embryo, namely the segregation of the ICM and TE lineages.
Citation: Keramari M, Razavi J, Ingman KA, Patsch C, Edenhofer F, et al. (2010) Sox2 Is Essential for Formation of Trophectoderm in the Preimplantation
Embryo. PLoS ONE 5(11): e13952. doi:10.1371/journal.pone.0013952
Editor: Martin Pera, University of Southern California, United States of America
Received June 1, 2010; Accepted October 6, 2010; Published November 12, 2010
Copyright:  2010 Keramari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Greek State’s Scholarship Foundation (IKY-Greece), Infertility Research Trust (UK), Medical Research Council (MRC/UK, R107358) and Deutsche
Forschungsgemeinschaft (DFG, ED79/1-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sue.kimber@manchester.ac.uk
Introduction
Sox genes are expressed throughout embryogenesis and encode a
subclass of high mobility group (HMG) box proteins driving cell fate
decisions by acting as transcription factors and architectural
components of chromatin [1,2]. Sox2 is developmentally regulated
[3] and is detected in the inner cell mass (ICM) of the murine
blastocyst [4] and subsequently in primitive ectoderm, extraembry-
onic ectoderm [4] and the developing nervous system [5]. Expression
of Sox2 is observed in mouse and human eye lens [6]; in humans,
heterozygous loss-of-SOX2 function causes several defects including
bilateral anophthalmia [7], and defects in the hypothalamo-pituitary-
gonadal axis [8]. It is essential for inner ear sensory organ [9] and taste
bud sensory cell [10] development. Sox2 acts cooperatively with the
pluripotency factor Oct4 at promoters activating transcription of Fgf4,
Utf1 and Fbx15 genes [11–13], and interacts with Nanog in regulating
transcriptionofRex1 [14]. It has been reported that the crucial rolefor
Sox2 in mouse embryonic stem (ES) cells is to maintain them in a
pluripotent state by preserving the required level of Oct4 expression
[15]. Furthermore, mouse embryonic and adult fibroblasts can be
induced to a pluripotent state in vitro through ectopic expression of
the transcription factors Sox2, Oct4, c-Myc and Klf4 [16,17,18].
Sox2 expression is essential during embryogenesis; Sox2 homozy-
gous null embryos die soon after implantation [4] and Sox2 is the
earliest marker of inner cells prior to ICM formation [19].
Furthermore, Sox2 in association with the POU domain transcrip-
tion factor Oct4 and homeobox transcription factor Nanog form a
regulatory core, which maintains self-renewal of the pluripotent
ICM in the embryo and ES cells [4,15,20–21], and is unique to
mammals [22]. A contiguous pair of highly evolutionarily conserved
Oct- and Sox-binding sites is essential for activating expression of
genes specific to the pluripotent state in ES cells [23]. Sox2
transcription is regulated by an enhancer containing this composite
Sox-Oct cis-regulatory element that Sox2 and Oct4 bind synergis-
tically [24]. This element also occurs within the proximal promoter
of Nanog [21], essential for retaining pluripotency [25,26]. The
Sox2-Oct4-Nanog regulatory complex controls expression of
pluripotency genes through feed-forward loops [22] including these
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target genes essential for self-renewal, the Sox2-Oct4-Nanog
complex represses genes initiating differentiation [28].
Blastocyst formation coincides with demarcation of the first two
lineages in the mammalian preimplantation embryo: the ICM that
gives rise to the embryo proper, extraembryonic endoderm and
mesoderm, and the trophectoderm (TE) that generates the
placenta [29,30]. ES cells are derived from the ICM/epiblast
population of the blastocyst [31–34]. Although this is a transitory
cell-population in the embryo, cultured ES cells can undergo
unlimited self-renewal and are pluripotent, giving rise to all
embryonic cell types. At the late blastocyst-stage, three distinct cell
lineages are observed: the epiblast, the primitive endoderm (PE)
and the trophectoderm [35]. Key binary switches in the mouse
blastocyst are regulated by pairs of transcription factors [36,37]
that govern cell fate decisions. Oct4, Sox2 and Nanog are
fundamental regulators maintaining undifferentiated ES cell and
epiblast fate [4,20,25,26], while caudal-type homeobox transcrip-
tion factor Cdx2 regulates TE gene expression and maintenance in
the mouse blastocyst, repressing Oct4 and Nanog in the TE [38].
Recently Gata3 has been demonstrated to regulate trophoblast
development in parallel to Cdx2, and both genes are dependent on
a third gene, Tead4 [39,40]. Gata6 regulates PE genes [41]
antagonising Nanog within the mouse blastocyst [42]. In addition,
the Spalt transcription factor Sall4 has been reported to regulate
transcription of Pou5f1 (encoding Oct4) and thereby formation of
the ICM-derived lineages, namely the epiblast and the PE [43,44].
Fgf4, regulated by the Sox2-Oct4 synergy [13], is expressed in
the ICM [45] and has a role in ICM maintenance as well as
trophoblast stem cell proliferation [37]. It has been suggested that
Fgf4 could have a paracrine effect in inducing polar TE, adjacent
to the ICM [46]. Fgf4 interacts with the receptor Fgfr2 [47] which
is expressed by the TE and extraembryonic ectoderm [48]. Cdx2
and Eomesodermin (Eomes), a T-box transcription factor
expressed in TE and responsible for its proliferation [38,49], have
been suggested as potential down-stream targets of Fgf4 signalling
[46]. Regulation of these gene families have also been associated
with Fgf4 signalling in Danio rerio and Xenopus laevis [50,51].
Homozygous Sox2 knock-out embryos die soon after implanta-
tion [4]. Implantation sites lacked the epiblast and extraembryonic
ectoderm components although trophoblast giant cells could be
distinguished. In culture, Sox2 null embryos formed abnormal
outgrowths lacking an ICM. Sox2 homozygous mutant embryos
could be rescued by wild-type ES cells suggesting cell autonomous
function. However by targeted deletion of the Sox2 gene, only
mRNA from Sox2 zygotic transcription can be eliminated; any
persisting maternal Sox2 mRNA or protein in the preimplantation
embryo might fulfill earlier essential roles. We have addressed the
question of an earlier role for Sox2 in controlling cell fate decisions
using RNAi, which removes both maternal and embryonic Sox2
mRNA present during the preimplantation period. By depleting
both sources of Sox2 mRNA at the 2-cell stage and monitoring
embryo development in vitro, we showed that in the absence of
Sox2, embryos arrest at the morula stage, and they fail to form TE
or to cavitate. Furthermore, by performing rescue experiments
using cell-permeant Sox2 protein, we observed reversal of the
Sox2-siRNA phenotype, as demonstrated by blastocyst formation
and expression of ICM, as well as TE markers.
Results
Sox2 expression in mouse preimplantation development
Temporal and spatial expression of Sox2 protein was examined
in preimplantation mouse embryos by immunofluorescence. Sox2
protein was found in oocytes and 2-cell stage embryos; fluorescence
intensity increased from the 4-8-cell stage to the morula stage,
peaking at the blastocyst, where it waspresentin both TE and ICM.
Sox2 protein was located in nuclei in cleavage stage embryos,
although nuclear staining at the 2-cell stage was weak and
cytoplasmic staining was observed. However in some 4-cell
embryos, Sox2 was localized in nuclei in all blastomeres, while in
others, nuclear localization was observed in half of the blastomeres,
while still in others Sox2 staining was detected only in the cytoplasm
and not in nuclei (Figure 1A). In blastocysts it was observed in some
nuclei and cytoplasm of TE as well as in all ICM nuclei (Figure 1A).
Pluripotent mouse ES cells and ES cells induced to form neural
lineages were used as positive controls for Sox2 immunostaining
(Figure S1A). Western blotting with the Sox2 antibody on protein
extracts from mES cells revealed a single band of 37 kDa, the
expected size for Sox2 protein (Figure S1B). To confirm these
results, Sox2 transcripts were also detected by RT-PCR at the
oocyte,2-cell, 4-cell,8-cell, morula andblastocyststages(Figure 1B).
Role of Sox2 in mouse preimplantation development
Sox2 was transiently knocked down in 2-cell MF1xCD1 embryos
with three different siRNA duplexes using electroporation.
Duplexes for an irrelevant protein, Firefly Luciferase, and
Galanin, a protein expressed throughout preimplantation mouse
development (J. Razavi, D. Brison and S. Kimber, unpublished)
were used as controls. Electroporation efficiency was 100%, as
determined by rhodamine fluorescence detected immediately after
electroporation and penetration of the siRNA duplexes into both
cells of the 2-cell mouse embryos, which were compared to mock-
electroporated embryos to exclude any autofluorescence effects.
UV visualised embryos were not cultured further.
Sox2-siRNA duplexes were electroporated separately; embryos
were cultured and scored daily until day 4 and 5 of development
(plug = day 1), when control embryos were at the morula (16–32
cells) and blastocyst stage respectively. No difference in develop-
ment between groups was detected until day 4. The effects of the
three Sox2-siRNA duplexes are presented in Figure 2. On day 4,
the majority of embryos of all groups formed morulae (Figure 2A,
2C, 2E) at percentages from 60% to 73.5%. All Sox2-siRNA
duplexes were effective in perturbing development; by day 5, Sox2-
duplex-1 had led to developmental arrest of 24% of embryos at the
4-8-cell stage and 51.7% at the morula stage. Sox2-duplex-2
resulted in arrest mainly at the morula stage (71.5%). Sox2-duplex-
3 caused 69% arrest at the morula stage. Morulae were compact
and showed similar organization to control groups. Only 18.7% of
the Sox2-duplexes -1 and -2, and 21% of the Sox2-duplex-3-siRNA
embryos formed blastocysts, compared to 76.2% to 83% for
incubator, 61.8% to 62.5% for Galanin and 55.4% to 56.5% for
FFL controls respectively (Figures 2B, 2D, 2F and 3A). Thus
absence of Sox2 prevented mouse preimplantation embryos
developing beyond the morula stage. Sox2-duplex-1 appeared to
have a more severe effect than duplexes -2 and -3, since a greater
proportion of the embryos remained at the 4-8-cell stage rather
than forming compacted morulae.
In order to rule out that the effects observed were not specific to
the cross used (MF1xCD1), we also examined the effect of Sox2-
duplex-1-siRNA on MF1xMF1 embryos. As observed in the
MF1xCD1 embryos, after Sox2-siRNA knock-down .90% of the
embryos underwent compaction but arrested at the morula stage
(Figure S2).
To determine whether developmental arrest resulted from loss of
Sox2 protein, we assessed protein expression by immunofluores-
cencewiththreedifferent Sox2antibodies(Figures3B,3Dand S3) in
Sox2-siRNA treated embryos at days 4 and 5 (MF1xCD1). Control
Sox2 in the Early Embryo
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showed strong staining for Sox2 (Figure 3B). On both days, all
embryos in the Sox2-siRNA group that remained at the morula stage
were negative for Sox2 or showed extremely faint Sox2 staining.
However, embryos in this group which reached the blastocyst stage
on day 5, invariably showed Sox2 staining (Figure 3B), although
generallydecreasedcomparedtocontrolblastocysts.Thereforesome
of the Sox2-siRNA treated embryos may have escaped the RNAi
effect and maintained Sox2 levels sufficient for blastocyst develop-
ment. Compared to controls, there was a general delay in time of
formation of the few blastocysts within the Sox2-siRNA embryos.
Assessing levels of fluorescence after Sox2 staining, and dividing the
number of embryos negative for Sox2 by the total number of
embryos electroporated and examined per experiment, the knock-
down efficiency after siRNA was found to be 71%, whereas 29%
escaped the RNAi effect. Lethality of the Sox2-siRNA phenotype on
day 5 was confirmed by Trypan-Blue uptake (Figure 3B). The
majority (83%) of the knock-down embryos assessed for viability on
day 5, contained a significant number of necrotic (blue-stained) cells.
Therefore further follow-up of the Sox2-siRNA knock-down
phenotype (e.g. embryo transfer) was not possible.
The Sox2 knock-down was also confirmed by RT-PCR in pools
of 30 embryos. A loss of Sox2 transcript in day 4 Sox2-siRNA
morulae (Figures 4A and S4) was observed compared to incubator-
control (untreated) morulae, in which Sox2 transcripts were always
detected. To determine whether the developmental arrest of Sox2
RNAi treated embryos was associated with loss of other genes
(some of them Sox2 targets), we examined transcript expression of
Fgf4, Fgfr2, Oct4, Nanog, Cdx2, Eomes and Tead4 (Figures 4A and
S4). In embryos where Sox2 transcript was undetectable, Fgfr2
transcripts were barely visible, Fgf4, Cdx2, Eomes and Tead4
transcripts were untraceable after amplification of cDNA to 40
cycles, whereas Oct4 and Nanog transcripts remained unaffected
(Figures 4A and S4). Comparable transcript levels for Atp1b1
(ATPase, Na+/K+ transporting, beta 1 polypeptide), Gata3, Gata4
and Gata6 were detected in Sox2 knock-down morulae compared
to incubator-control morulae (Figure 4A). This implies that loss of
Sox2 led to down-regulation of Fgf4, Fgfr2, Cdx2, Eomes and Tead4
transcripts, but did not affect Oct4, Nanog, Atp1b1, Gata3, Gata4 and
Gata6 transcripts in the morula. Similar levels of beta-actin
transcripts (control) were detected in Sox2-siRNA and incubator-
control embryos.
Due to the similarity of sequence in the HMG domain (which
Sox2-duplex-1 targeted), between Sox2 and Sox1, Sox3, Sox14, Sox15
and Sox21, the presence of the latter transcripts was also
investigated to verify the specificity of the Sox2 knock-down.
Figure 1. Sox2 (protein and mRNA) expression in mouse preimplantation development. Expression of Sox2 was detected at all stages
(oocyte to blastocyst) of mouse preimplantation development by immunocytochemistry and RT-PCR. (A) Developmental stages of preimplantation
mouse embryos immunostained for Sox2 (Abcam): single optical sections of confocal Z-series. Bar: 50 mm. (B) RT-PCR for Sox2 and b-actin in mouse
preimplantation embryos, 40 cycles. Lane 1: Hyperladder IV (Bioline); 2: oocyte; 4: 2-cell; 6: 4-cell; 8: 8-cell; 10: morula; 12: blastocyst; 14: mES cells (line
E14); 16: genomic DNA (Bioline). Lanes (3, 5, 7, 9, 11, 13, 15): RT –ve controls for each developmental stage.
doi:10.1371/journal.pone.0013952.g001
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stage in control or knock-down embryos after siRNA for each of
the 3 duplexes (Figures 4A and S4). To confirm that the Sox2
knock-down phenotype was due to specific depletion of Sox2, we
performed rescue experiments using recombinant cell-permeant
Sox2 protein fused with a TAT protein transduction domain to
allow intracellular delivery, which has been previously shown to be
highly efficient in compensating for loss of RNAi-induced knock-
down of Sox2 in ES cells [52].
The cell-permeant Sox2 protein was added 24 h after RNAi in
the Sox2 siRNA group as well as incubator control embryos and it
was renewed every 24 h as reported in Materials and Methods. Up-
take of the Sox2-TAT protein was monitored by immunofluores-
cence 6 h, 12 h and 18 h after its first addition. Gradual increase in
Sox2 protein expression and signs of possible protein uptake
through an endocytic pathway were detected, as demonstrated by
the patchy Sox2 expression (Figure S5). A significant rescue
phenotype was observed among the Sox2 siRNA embryos by day
5 of development (Figures 2G, 3C and 3D). While 43–47.7% of the
Sox2 siRNA (duplexes 2 and 3) embryos arrested at morula stages
with only 18.7–21% forming blastocysts, their equivalent Sox2
siRNA R (rescue groups) formed blastocysts at percentages from
59.7% to 62.6% (Figures 2G, 3C), indicating substantial phenotype
reversal upon addition of the Sox2 protein in the Sox2 siRNA
groups. At the same time, 72.75% of the untreated incubator
control embryos formed blastocysts, whereas 50.9% of the embryos
treated with the cell-permeant Sox2 protein (Inc ctrl R) reached the
blastocyst stage (Figures 2G, 3C). A significant proportion of the
remaining incubator control Sox2-treated embryos appeared
perturbed at earlier stages, indicating some detrimental effect of
higher than normal levels of Sox2 in these embryos.
Loss of Sox2 does not affect Oct4 expression, influences
Nanog localization but not expression, but causes
downregulation of trophectoderm associated proteins
In order to investigate the Sox2-siRNA phenotype, we stained
embryos for a number of ICM and TE markers, expressed at the
morula and blastocyst stage (Figure 4B). Both day 4 and day 5
embryos were assessed after Sox2-siRNA for Sox2 protein
expression, which was shown to be almost or completely absent.
When Sox2-siRNA embryos were compared with incubator-
control embryos, reduction in a number of TE proteins was
observed. Yap, Cdx2, Eomes and Occludin were present in
control embryos but could not be detected or were weakly
detected in Sox2-siRNA embryos (Figures 3D and 4B). Fgfr2 and
Fgf4 proteins were also decreased (Figure 4B), coinciding with the
absence of transcripts for these and other TE markers (Tead4,
Cdx2, Eomes) in Sox2-siRNA embryos (Figures 4A and S4).
However, the early trophoblast stem cell marker Gata3, as well as
Oct4, Nanog, ZO1, Desmoplakin, E-cadherin, Gata4 and Gata6
protein expression remained unaffected (Figures 3D and 4B) by
Sox2 knock-down. Although Nanog protein was expressed in day 4
and day 5 in Sox2-siRNA embryos, it did not appear to be located
in the nuclei. In the absence of Sox2 transcripts in Sox2-siRNA
embryos, Oct4 and Nanog transcripts remained unaffected
(Figures 4A and S4). The rabbit polyclonal Cdx2 antibody gave
more prominent nuclear staining than the mouse monoclonal
Cdx2, however both stained TE nuclei and cytoplasm. Immuno-
logical controls for all antibodies were negative (Figure S6).
After reversal of Sox2 knock-down phenotype, day 5 Sox2-siRNA
R blastocysts expressed Sox2 in ICM and TE nuclei, Oct4 in ICM
nuclei and Yap and Cdx2 in TE nuclei, resembling the day 5
incubator control and control R blastocysts (Figures 3B, 3D, 4B).
The arrested day 5 Sox2-siRNA morulae did not demonstrate any
Sox2, Yap or Cdx2 staining but did express Oct4 in inner cell
nuclei (Figure 3D), resembling the originally observed Sox2 knock-
down phenotype (Figures 3B, 4B).
Sox2 transient knock-down induces apoptosis at day 5 of
development
Sox2-siRNA, FFL-siRNA and incubator-control embryos were
assessed for apoptosis at day 4 and 5 of development. While no
apoptotic cells were identified at day 4 in either the control groups
or the Sox2-siRNA groups, lack of Sox2 appeared to induce
increased apoptosis in day 5 Sox2-siRNA embryos (Figure 5A), as
indicated by an increased apoptotic index both in embryos with
#32 cells (Figure 5B) and in arrested morulae (Figure 5C). The
relative distribution of apoptosis between inner and outer cells
(ICM and TE, respectively, where blastocysts had formed) in
siRNA and control groups was the same (30% inner cells, 70%
outer cells), thus most of the apoptosis appeared to be in the outer
cells in all groups. Furthermore, Sox2 knock-down did not affect
total cell numbers when considering both morulae and blastocysts
at day 4 or 5 (Figure 6). Nevertheless, arrested morulae in the Sox2
knock-down group had lower cell numbers than control
blastocysts. To conclude, more apoptotic cells were observed in
Sox2 knock-down embryos compared to control embryos.
However when compared by morphology, morulae and blasto-
cysts (incubator-control versus Sox2-siRNA ‘escapee’ blastocysts) of
both groups contained the same number of cells.
Discussion
Sox2 expression in mouse preimplantation development
We found that Sox2 is expressed throughout preimplantation
mouse development with cytoplasmic or nuclear Sox2 protein
Figure 2. Development of MF1xCD1 (A,B,C,D,E,F) embryos in culture after RNAi, as well as rescue phenotype of MF1XCD1 (G)
embryos. (A,B) Sox2-duplex-1-siRNA embryos (hatched, N=112 day 4, N=107 day 5) were compared with incubator-control (grey, N=254 day 4,
N=244 day 5), Galanin-siRNA (white, N=265) and FFL-siRNA (black, N=139) embryos. Most day 4 (A) embryos formed morulae (16–32 cells), but 29%
of the Sox2-duplex-1-siRNA embryos remained at the 4-8-cell stage. On day 5 (B), while 76.2% of incubator-control embryos formed blastocysts, only
18.7% of the Sox2-duplex-1-siRNA embryos reached blastocyst stage. (C,D) Sox2-duplex-2-siRNA embryos (hatched, N=212 day 4, N=137 day 5)
were compared with incubator-control (grey, N=366 day 4, N=274 day 5), Galanin-siRNA (white, N=265) and FFL-siRNA (black, N=139) embryos.
Most day 4 (C) embryos formed morulae, but 14.4% of the Sox2-duplex-2-siRNA embryos remained at the 4-8-cell stage. Only 18.7% of the day 5 (D)
Sox2-duplex-2-siRNA embryos formed blastocysts. (E,F) Sox2-duplex-3-siRNA embryos (hatched, N=90 day 4, N=30 day 5) were compared with
incubator-control (grey, N=112 day 4, N=30 day 5), Galanin-siRNA (white, N=92 day 4, N=30 day 5) and FFL-siRNA (black, N=83 day 4, N=30 day 5)
embryos. Most day 4 (E) embryos formed morulae, while 15% of the Sox2-duplex-3-siRNA embryos remained at the 4-8-cell stage. Only 21% of the
day 5 (F) Sox2-duplex-3-siRNA embryos developed to blastocysts. (G) Rescue phenotype at day 5 of development of MF1xCD1 embryos. Only 21.1%
of Sox2-duplex-2-siRNA embryos (N=64) and 25.4% of Sox2-duplex-3-siRNA embryos (N=65) formed blastocysts. After treatment with cell-permeant
Sox2 protein, 62.6% of Sox2-duplex-2-siRNA R embryos (N=66) formed blastocysts and 59.7% of the Sox2-duplex-3-siRNA R embryos (N=62) reached
blastocyst stage. 72.75% of untreated incubator control embryos (N=122) formed blastocysts but treatment with cell-permeant Sox2 protein
(N=128) reduced this to 50.9%. In all cases, chi-square tests revealed significant differences (p,0.0001) between the % of Sox2-siRNA, control and R
morulae, as well as between the % of Sox2-siRNA, control and R blastocysts.
doi:10.1371/journal.pone.0013952.g002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13952Figure 3. Sox2 expression in Sox2-siRNA and control MF1xCD1 embryos. (A) Phase contrast images of day 5 incubator-control, FFL-siRNA, and
Sox2-duplex-1, -2 and -3 siRNA embryos. While control embryos formed blastocysts, most Sox2-siRNA embryos did not. Bars: 100 mm. (B) Control and
Sox2-duplex-2-siRNA embryos stained for Sox2 (Abcam) on days 4 and 5: single optical sections from confocal Z-series, DAPI-stained nuclei (blue) and
Sox2 (green); bar: 50 mm. Decreased Sox2 protein expression was observed in Sox2 knock-down morulae on day 4, which persisted on day 5. Absence
of Sox2 protein on day 3, as a result of the Sox2-siRNA knock-down on day 2, was also confirmed. A few blastocysts forming on day 5 within the Sox2-
siRNA group (‘escapees’ from the siRNA effect) showed some Sox2-staining, although less than incubator-control blastocysts. The lethality of the Sox2-
siRNA phenotype on day 5 was assessed by Trypan Blue up-take. Presence of non-viable (blue) cells was apparent in 10 out of the 12 day 5 Sox2-siRNA
embryos examined. (C) Rescue phenotype in MF1xCD1 embryos: Sox2-siRNA and incubator-control embryos were cultured with and without cell-
Sox2 in the Early Embryo
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finding is partially in agreement with Avilion et al. [4] who showed
that Sox2 protein was present in the cytoplasm of the fertilized
oocyte, but its translocation into nuclei occurred at the 2-cell stage.
Moreover, in our study, Sox2 transcripts of maternal origin were
detected in oocytes and Sox2 protein was found in both nucleus and
cytoplasm of the oocyte. Some 4-cell embryos had mainly
cytoplasmic staining while others mainly nuclear; indeed some had
blastomeres in both categories. This may relate to the increasing
zygotic transcription at the 4-cell stage and suggests that Sox2
nuclear translocation may be initiated a bit later, at the 4-cell stage,
in the strain of mice we examined compared to that used by Avilion
et al. In later cleavage-stage embryos nuclear staining was invariably
observed. The strong expression of Sox2 in TE and ICM at the
blastocyststageisgenerallyinagreementwithAvilionetal.[4].They
showed that in early blastocysts Sox2 was uniquely cytoplasmic in
TEcells,whereaswe observed nuclearand cytoplasmicexpression of
Sox2 in some TE cells. They reported that Sox2 was mostly nuclear
in ICM and our observations are in agreement.
Role of Sox2 in mouse preimplantation development
The aim of our study was to define the effect of knocking down
Sox2 in developing preimplantation mouse embryos, in order to
uncover early functions in maintaining developmental potential of
early mouse embryos and marking the pluripotent lineage [53].
After knock-out, in the absence of zygotic Sox2, the epiblast was
not maintained but rather differentiated into diverse cell types [4].
The authors suggested that maternal Sox2 protein derived from
the oocyte may carry the embryo through preimplantation
development in the absence of oocyte Sox2 mRNA. However, in
our study Sox2 transcripts were detected in oocytes and siRNA for
Sox2 led to developmental arrest at the morula stage, suggesting a
significant contribution of maternal Sox2, and that Sox2 protein
and transcripts are crucial in the mouse preimplantation embryo
for an additional earlier cell function than previously described.
When Sox2-siRNA is applied early in preimplantation develop-
ment, Sox2 protein levels are barely detectable or absent 3 days
later, confirming the efficacy of siRNA as a technique for
examining preimplantation protein function [54–56]. After
knocking down Sox2 in 2-cell mouse embryos with three different
siRNA duplexes, most morulae had very low levels of Sox2 and
failed to develop to blastocysts, while this effect was not seen in
control groups. The slightly smaller numbers of blastocysts
forming after Galanin- and FFL-siRNA compared with incubator-
control embryos suggests that the technique of siRNA causes some
stress to embryos, but without statistically significant effect on
development. This is further supported by the viability and normal
post-implantation development following Galanin siRNA by
electroporation in 2-cell stage mouse embryos and subsequent
embryo-transfer at the blastocyst-stage to pseudopregnant mice (J.
Razavi, D. Brison and S. Kimber, unpublished). The difference of
severity of the Sox2 knock-down outcome when using the two
different crosses (MF1xMF1, MF1xCD1) may be explained in the
light of different genetic background and possibly dosage or
polymorphisms of interacting genes of the mouse strains [57,58].
Sox2-duplex-1 had a stronger impact on developing mouse
embryos than duplexes -2 and -3, causing a proportion of them to
arrest earlier, namely at the 4-8-cell stage. However, the Sox2-
duplex-1 was designed to target within the conserved region of the
HMG box, and might affect additional genes. We have controlled
for this by using two siRNA sequences designed outside the HMG
box and targeting Sox2 alone. In thiscase,formostofthe Sox2knock-
down embryos developmental arrest occurred at the transition from
the morula to the blastocyst stage, with Sox2-siRNA morulae failing
to cavitate or undergo cell division beyond the 32-cell stage.
However, a small number of Sox2-siRNA embryos ‘escaped’ the
RNAi effect. These developed to blastocysts and showed moderate
levels of Sox2 protein expression, though generally lower than
control blastocysts. This indicates that in some embryos knock-down
is incomplete, allowing sufficient Sox2 protein to accumulate by the
latemorulastagetopermitdevelopmenttotheblastocyststage.Thus
a threshold level of Sox2 might be required for the developmental
transition from a compacted morula to a fully differentiated
blastocyst. Furthermore, Sox2-siRNA ‘escapee’ embryos were
generally delayed in forming blastocysts compared to incubator-
control embryos, whereas arrested Sox2-siRNA morulae did not
form TE or a cavity when left in culture. This observation was
further supported by confirming the lethality of the Sox2-siRNA
phenotype on day 5, with the majority of the embryos becoming
necrotic, as indicated by incorporation of Trypan-Blue.
After rescue experiments, using Sox2 protein fused with a TAT
protein transduction domain [52], the Sox2-siRNA phenotype was
reversed and blastocysts were formed. This confirms that Sox2
depletion was indeed the cause of the siRNA induced phenotype.
The same cell-permeant Sox2 protein has been successfully used to
rescue the stem cell phenotype observed in mES cells after Sox2-
siRNA knock-down [52]. Indeed, a series of recent publications
demonstrate that TAT-mediated protein transduction is an efficient
strategy to deliver biologically active proteins such as transcription
factors into a variety of cells [59–61], also reviewed in [62].
Loss of Sox2 does not affect Oct4 and Nanog expression,
but causes downregulation of trophectoderm associated
proteins
Loss of Tead4 (a molecule recently shown to be essential for TE
formation in preimplantation mouse embryos [39]), Cdx2 and
Eomesodermin, as well as the Tead4 coactivator protein Yap,
(which localizes in nuclei of outer TE cells before Cdx2 does [39]),
occurred after Sox2 knock-down in mouse embryos. Moreover,
regular expression of all these genes after Sox2-mediated rescue of
blastocysts, indicates that Sox2 may regulate genes that control
differentiation of the outer cells of the morula to form TE. This is
permeant Sox2 protein, and embryo development was assessed up to day 5. Phase contrast images of blastocysts from untreated day 5 incubator-
control embryos (Day 5 Inc Ctrl); Lack of blastocyst formation in untreated day 5 Sox2-siRNA (duplex-2) embryos (Day 5 Sox2 siRNA); Blastocysts and
some arrested embryosin day 5 controlembryostreated with cell-permeant Sox2 protein (Day 5 Inc Ctrl R); Rescue phenotype on day 5 with blastocyst
formation as well as some arrested embryos after treatment of Sox2-siRNA (duplex-2) embryos with cell-permeant Sox2 protein (Day 5 Sox2 siRNA R).
Bars: 100 mm. (D) Comparison of D5 Sox2 siRNA embryos with untreated incubator control embryos (D5 Inc ctrl), as well as with rescued D5 Sox2 siRNA
R embryos and D5 Inc ctrl R embryos for Sox2 (R&D), Oct4 (BD Biosciences), Cdx2 (Biogenex) and Yap (Cell Signaling) proteins. The images are single
optical sections from confocal Z-series. Untreated D5 Inc ctrl blastocysts expressed Sox2 in ICM and TE nuclei, Oct4 in ICM nuclei, Cdx2 and Yap in TE
nuclei; D5 Sox2 siRNA arrested morulae did not demonstrate Sox2, Cdx2 and Yap staining, but expressed Oct4 in inner cell nuclei; D5 Inc ctrl R
blastocysts showed similar expression patterns with D5 Inc ctrl blastocysts for all 4 markers; rescued D5 Sox2 siRNA blastocysts expressed Sox2 in ICM
and TE nuclei,Oct4 in ICM nuclei, Cdx2and Yap in TE nuclei,indicating reversal of the Sox2siRNA phenotype.At least 10 embryoswere stained for each
antigen and representative embryos are shown. Similar results were obtained for both Sox2 siRNA duplexes. Blue indicates DAPI stained nuclei and
green/red staining for the protein of interest. In all cases immunological controls were negative (Figure S6). Bars: 100 mm.
doi:10.1371/journal.pone.0013952.g003
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PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13952Figure 4. Assessment of ICM and TE markers in Sox2-siRNA and control MF1xCD1 embryos. (A) RT-PCR for Sox2, Fgfr2, Fgf4, Cdx2, Eomes,
Tead4, Oct4, Nanog, Sox1, Sox3, Sox14, Sox15, Sox21 and beta-actin (40 cycles) on day 4: incubator-control embryos (lane 1); Sox2-duplex-2-siRNA
embryos (lane 2); genomic DNA (lane 3); incubator-control morulae –RT (lane 4); Sox2-duplex-2-siRNA morulae –RT (lane 5). In the absence of Sox2
transcript after siRNA, a clear reduction of Fgfr2, Ffg4, Cdx2, Eomes and Tead4 transcripts in Sox2-siRNA embryos was observed. Oct4 and Nanog
transcripts were unaffected in Sox2 knock-down morulae compared to incubator-control morulae. To ensure absence of signal did not reflect low
detectable message, we performed PCR at 40 cycles. PCR for all transcripts was determined at 25, 30 and 35 cycles with results similar to those
presented, but with weaker band intensity where present. Sox1, Sox3, Sox14, Sox15 and Sox21 transcripts were not detected in incubator-control
morulae or Sox2 knock-down morulae. Atp1b1 (ATPase, Na+/K+ transporting, beta 1 polypeptide), Gata3, Gata4 and Gata6 transcripts were detected
in comparable levels in Sox2 knock-down morulae compared to incubator-control morulae. Beta-actin transcripts were detected in both Sox2-siRNA
and incubator-control embryos. This figure illustrates Sox2-duplex-2-siRNA embryo transcripts, whereas similar patterns of transcript expression for
Sox2-siRNA duplexes -1 and -3 are shown in Figure S4. (B) Comparison of Sox2 knock-down embryos (as assessed by absence of fluorescence after
Sox2 staining) with incubator (untreated) control embryos for ICM and TE markers. Immunofluorescence for Sox2 (Abcam), Oct4, Nanog, Cdx2 (rabbit
polyclonal from Jane Collins), Eomes, Fgfr2, Fgf4, Occludin, ZO1, Desmoplakin, E-cadherin, Gata4 and Gata6 to compare protein expression between
incubator control and Sox2-siRNA embryos at day 4 and 5 of preimplantation development. The images are single optical sections from confocal Z-
series. Sox2-duplex-1-siRNA embryos stained for Sox2 are shown in this Figure. In all cases, after knock-down with each of the three duplexes, Sox2
siRNA embryos were negative for Sox2. For assessment of the other markers, embryos from all three knock-down construct groups were pooled. A
large reduction in Sox2, Cdx2, Eomes, Fgfr2, Fgf4 and Occludin protein was observed, whereas Oct4, Nanog, ZO1, Desmoplakin, E-cadherin, Gata4
and Gata6 remained unaffected. However, Nanog staining appeared more cytoplasmic in Sox2 knock-down embryos. The selected image for the day
4 incubator control embryo stained for Cdx2, is a plane through the top of the embryo and the positively stained Cdx2 cell in the center is located in
the outer layer of the embryo. The staining patterns for Sox2 and Cdx2 were confirmed with different Sox2 (Chemicon) and Cdx2 (Biogenex)
antibodies (Figure S3). At least 10 embryos were stained for each antigen and representative embryos are shown. Blue indicates DAPI stained nuclei
and green staining for the protein of interest. In all cases immunological controls were negative (Figure S6). Where antibodies were compatible,
embryos were double-stained for two markers. In all cases the anti-Sox2 staining for Sox2-siRNA embryos was negative. Bar: 50 mm.
doi:10.1371/journal.pone.0013952.g004
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13952Figure 5. Assessment of apoptosis in embryos using the TUNEL assay. (A) Fluorescence analysis for apoptotic cells; the images are single
optical sections from confocal Z-series. The fragmented nuclei (green fluorescence) are apoptotic (white arrows). i. Day 5 incubator-control embryo; ii.
Day 5 Sox2 knock-down embryo; iii. Controls for the TUNEL reaction (positive control top; negative control bottom; blue DAPI); iv. Day 5 FFL-siRNA
embryo. Bars: 50 mm. (B) Mean apoptotic indices in embryos with #32 cells on day 5. Sox2-siRNA embryos (white, N=27) were compared with
incubator-control embryos (black, N=26) and FFL-siRNA embryos (grey, N=25). Independent samples T-test revealed significant difference
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PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13952supported by the reduction in cell surface expression of Occludin,
a component of tight junctions [63]. However since ZO1,
Desmoplakin and E-cadherin protein expression, as well as
Na+/K+-ATPase b-subunit (Atp1b1) transcript expression were
not affected, the initiation of epithelia formation appears to be
intact in Sox2 knock-down embryos. The absence of Fgfr2 in Sox2-
siRNA embryos also implies malfunction of the outer cells of the
embryo, whereas the reduction of Fgf4, a direct target gene of the
Sox2-Oct4 synergy, would reflect malfunction of the ICM [64]. In
this respect, the identification of Sox2 transcripts as the earliest
marker of inner cells of the embryo should be noted [19]. Tead4
2/2 embryos [39] arrested at the morula stage, did not form
blastocyst cavities and downregulated TE associated markers
Cdx2, Eomes and Fgfr2. Similarly, in Tead4 2/2 arrested
morulae, E-cadherin was not affected [39]. The striking similarity
between the Sox2 RNAi embryo phenotype and that of the Tead4-
null embryos, suggests a potential link. The early trophoblast
marker Gata3 is expressed along with Cdx2 during preimplanta-
tion development and also maintained by Tead4 although
expressed independently of Cdx2 [40]. Gata3 also regulates
trophectoderm, but it did not seem to be affected by the absence of
Sox2 in our study, implying the existence of still poorly defined
transcription factor circuitries affecting cell fate decisions [65].
Sox2 knock-down did not affect total cell numbers up to the
morula stage (days 3–4). However, whilst control embryos cultured
up to day 5 (approximately 72 h post 2-cell stage) reached roughly
64 cells and formed blastocysts, Sox2 knock-down embryos did not
progress beyond 30 cells. In Tead4 2/2 embryos cell division
occurred on schedule up to 60 h post 2-cell stage, reaching 32 cells
and a morula-like morphology, which was maintained, as embryos
did not form clear blastocyst cavities. The authors stated that cell
proliferation in the Tead4 2/2 embryos was not arrested or
significantly delayed [39] although they did not examine cell
numbers later than 60 h post 2-cell. In our study, Sox2 RNAi
embryos also failed to form blastocyst cavities and arrested at the
morula stage. Sox2 may facilitate the maintenance of cell division
in the embryo of Oct4 +ve cells, since embryos did not continue
beyond the 30-cell stage when it was depleted. Sox2 could
potentially regulate TE formation in the preimplantation embryo
at some point upstream of Tead4, since Tead4 expression is
affected in the absence of Sox2 (this study) but Sox2 is not affected
in the absence of Tead4 [39]. The lack of blastocyst cavity
formation observed in our Sox2 RNAi embryos, as well as in the
Tead4 2/2 embryos [39], suggests a more severe phenotype than
in Cdx2 2/2 embryos, which gradually cavitate despite the
absence of Cdx2 [38]. Furthermore, whilst Sox2 RNAi and Tead4
2/2 embryos downregulate Cdx2, Eomes and Fgfr2, Cdx2 2/2
embryos express Eomes (though weakly) and Fgfr2 [38]. In
addition, the absence of the Tead4 co-activator and upstream
Cdx2 regulator protein, Yap, in day 5 Sox2-siRNA embryos, but its
presence in the rescued Sox2-siRNA blastocysts, make Sox2 a likely
early regulator in the sequence of events leading to TE formation
(p,0.0001) between apoptotic indices of Sox2-siRNA and incubator-control as well as FFL-siRNA embryos with #32 cells. (C) Mean apoptotic indices
for day 5 mouse embryos. Sox2-siRNA embryos (white, N=33) were compared with incubator-control embryos (black, N=32) and FFL-siRNA embryos
(grey, N=33). Independent samples T-test revealed a significant difference (p=0.003) between apoptotic indices of Sox2-siRNA and incubator-control
or FFL-siRNA morulae. There was no statistically significant difference (p=0.2) between apoptotic indices of Sox2-siRNA escapee blastocysts,
incubator-control and FFL-siRNA blastocysts. Embryos from all three Sox2 knock-down groups were pooled.
doi:10.1371/journal.pone.0013952.g005
Figure 6. Assessment of cell number per embryo. Cell number per embryo in Sox2-siRNA (grey) and incubator-control morulae and blastocysts
(black) at days 4 and 5 of preimplantation development. The Sox2-siRNA embryos were confirmed to be Sox2 knock-down embryos, as assessed by
absence of fluorescence after Sox2 immunostaining. Day 4 Sox2-siRNA morulae (d4 mor S, N=26) were compared with day 4 incubator-control
morulae (d4 mor I, N=26) and day 4 Sox2-siRNA blastocysts (d4 blast S, N=4) were compared with day 4 incubator-control blastocysts (d4 blast I,
N=4). Day 5 Sox2-siRNA morulae (d5 mor S, N=26) were compared with day 5 incubator-control morulae (d5 mor I, N=4) and day 5 Sox2-siRNA
blastocysts (d5 blast S, N=4) were compared with day 5 incubator-control blastocysts (d5 blast I, N=26). Chi-square tests revealed that there was no
statistically significant difference between these groups. Thus arrested Sox2-siRNA morulae remain at the cell number for the morula stage when
control embryos have divided further and formed blastocysts. Embryos from all three Sox2 knock-down groups were pooled.
doi:10.1371/journal.pone.0013952.g006
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rescued Sox2-siRNA blastocysts express protein for Sox2 in ICM
and some TE nuclei, Oct4 in ICM nuclei, as well as Cdx2 and
Yap in TE nuclei, and now form blastocysts, is also consistent with
Sox2 involvement in regulating the trophectoderm associated
markers Yap and Cdx2, whether directly or indirectly.
In our study, the pluripotency marker proteins Oct4 and Nanog
remained unchanged despite the lack of Sox2. This is surprising
taking into account their interconnected regulation in ES cells. A
similar maintenance of pluripotency markers was also observed in
the absence of Tead4 [39]. Enhancers of a number of pluripotency
associated genes contain a Sox-Oct element, which both Sox2 and
Oct4 bind in a combinatorial interaction [24]. The complex formed
regulates several genes (among them Oct4 and Sox2 themselves, as
well as Nanog) that have been identified as essential for the formation
of the ICM during mouse preimplantation development and for
self-renewal of pluripotent ES cells [4,20,25,26]. The retention of
Oct4 and Nanog expression, despite the depletion of Sox2 in this
study, should be viewed in the light of their own auto-regulation
which is likelytoallow theirtranscriptionandtranslation eveninthe
absence of Sox2. Alternatively, the well described trio-motif-
network of Sox2-Oct4-Nanog might not function at the morula
stage, so that Oct4 and Nanog can persist in the absence of Sox2.
Thisnetwork may only come intoforce at the blastocyststage, when
formation of the ICM leading to the epiblast occurs. However,
Nanog expression appeared more cytoplasmic in Sox2-siRNA
embryos compared to controls. Since Nanog is first expressed at
the late morula stage [25,26], it is likely that after Sox2 knock-down,
embryos arrest at about the time Nanog is first transcribed/
translated and hence staining may represent newly synthesised
cytoplamic protein, not yet translocated into the nucleus [25,26].
Since the Sox2 knock-down embryos are delayed compared to
controls, this might explain why control morulae already show a
strong nuclear Nanog signal.
Fgf4 is expressed at the blastocyst stage [45,66] and regulates
the 5
th cell cycle in the mouse embryo [67]. Thus loss of Fgf4 could
account for the predominance of morulae with less than 32 cells
after Sox2-siRNA. Later Fgf4, originating from the ICM and
epiblast, acts upon TE cells in a paracrine manner [37]. The Fgf4
gene has both core HMG and POU regulatory elements that are
mutually dependent, and an additional independent Sox2-binding
HMG regulatory element [68–70]. In Sox2-siRNA embryos both
Fgf4 and Fgfr2 were downregulated, and there were almost
undetectable levels of the TE markers Cdx2 and Eomes. FGF
signalling is essential for the regulation of Cdx1, Cdx2 and Cdx4
during gastrulation in Xenopus laevis [71]. Therefore it is possible
that Fgf4/Fgfr2 signalling induces Cdx2 and Eomes, thereby
facilitating TE formation. On the other hand Sox2 may be
required in early cells expressing Cdx2 or for its maintenance. In
its absence, Cdx2 is not expressed, with concurrent lack of Eomes
and Fgfr2 expression. It has previously been shown that Eomes is
downstream of Cdx2 in TE differentiation [38,49]. Furthermore,
the parallel expression of Fgfr2 and Cdx2 in outer cells of the
preimplantation embryo [48], and the established role of FGF
signalling at the 5
th cell cycle when overt TE is generated [67],
could imply a concurrent requirement for FGF signalling with
Cdx2 expression during TE development. The association of Sox2
and Cdx2 genes has also been shown in a different system, that of
gastric cancer where Sox2 and Cdx1/Cdx2 are inversely related
[72,73]. Interestingly, the extra-embryonic endoderm markers
Gata4 and Gata6 were not affected by Sox2-siRNA, showing
similar patterns of expression as previously reported [74,75]. Our
finding therefore reinforces previous observation that Sox2 does
not seem to exert an effect on extra-embryonic endoderm [4].
Recent findings in mES cells show an inverse relationship
between Sox2 and TE associated markers, as ES cells can
differentiate into trophectoderm in the absence of Sox2 [15,76,
Keramari, Ward and Kimber unpublished]. However ES cells are
derived from the ICM, generally from blastocysts in implantation
delay, and are a completely different cell population to the
cleavage and morula stage embryo investigated in our study.
Murine ES cells do not, unless experimentally forced, differentiate
to TE [77], while the outer cells of the morula spontaneously
differentiate to TE in utero or in simple media in vitro [78].
Furthermore, the cross-talk between ICM and TE that takes place
in the embryo is different from the signalling between ES cells in
culture. It has also been shown that Sox proteins can act either as
activators or repressors in different cellular contexts [79], and that
critical thresholds of Sox2 are associated with different phenotypes
in early cell lineage commitment events in neural and foregut
endoderm differentiation [80,81]. This could explain the obser-
vation that Sox2 seems to positively regulate Cdx2 and Eomes in
the morula, but to repress both genes in ES cells [15,76, Keramari
et al. unpublished]. For example, it has been reported that a single
transcription factor, namely Sall4, regulates two distinctively
different stem cell populations within the blastocyst, ES cells
arising from the ICM, and XEN stem cells originating from the
extra-embryonic endoderm [82]. Sall4 is interconnected with the
Sox2, Oct4 and Nanog auto-regulatory circuit to preserve
pluripotency of ES cells, but at the same time induces genes
critical for extra-embryonic endoderm formation like Gata4, Gata6,
Sox7 and Sox17 [82]. Furthermore, it was recently shown that the
transcription coactivator Yap, previously thought to regulate only
trophectoderm in the mouse embryo [39], also seems to exert a
role in regulation of self-renewal and differentiation in mouse ES
cells [83]. This illustrates the common finding that transcriptional
regulators of lineage segregation events can exert distinctly
different functions within closely associated cell populations. In
addition, it has been demonstrated that Nanog, previously thought
to be a core transcription factor of the network that regulates
pluripotency, though essential for ICM and germ cell formation, is
dispensable for murine ES-cell self-renewal [84].
Our results lead us to conclude that Sox2 plays two distinctively
different roles at two different early developmental stages, namely
the morula and the ICM-derived ES cells and early epiblast
[4,15,19, our data]. In addition, the association of Sox2 with Yap/
Tead4/Cdx2/Eomes/Fgfr2 expression and TE formation in the
early mouse embryo arising from our study suggests Sox2 may
play a role in regulation of TE fate.
Sox2 transient knock-down induces apoptosis at day 5 of
development
Sox2-siRNA embryos showed higher levels of apoptosis
compared to incubator-control and FFL-siRNA embryos at day
5 of development. Electroporation did not appear to cause
increased apoptosis, since FFL-siRNA embryos exhibited similarly
low levels of apoptosis to the incubator-control embryos.
Therefore knock-down of Sox2 seems to induce apoptosis,
suggesting that Sox2 may regulate survival factors. Interestingly,
in all groups, there were more apoptotic cells among outer (TE)
cells than inner (ICM) cells. This may indicate a strain difference
since most studies [85,86] revealed higher apoptosis in the ICM
than trophectoderm of mouse embryos cultured from the zygote to
the blastocyst stage. Although many studies have shown equal
levels of apoptosis between ICM and TE in human embryos,
Hardy et al. [87] reported increased apoptosis in TE. Strumpf
et al. [38] demonstrated that Cdx2 disruption caused peri-
implantation embryonic lethality due to lack of establishment of
Sox2 in the Early Embryo
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polarisation for TE commitment, but ultimately cells underwent
apoptosis. The potential link between Sox2 and Cdx2, revealed by
our study, concurs with the similar induction of apoptosis when
either Sox2 or Cdx2 are eliminated.
In summary, after knocking down Sox2 in 2-cell stage mouse
embryos using siRNA, most embryos arrested at the morula stage
and apoptosis was increased. While pluripotency markers Oct4
and Nanog remained unaffected, trophectoderm markers Tead4,
Yap, Cdx2, Eomes and Fgfr2 were downregulated. The RNAi
phenotype was rescued by introduction of Sox2 protein fused with
a TAT protein transduction domain, leading to blastocyst
formation and re-expression of Sox2, Yap and Cdx2. This
indicates that Sox2 plays an important role in the preimplantation
mouse embryo and its earliest essential function appears to involve
establishment of the trophectoderm lineage either by directly or
likely indirectly regulating Tead4 and Cdx2, or alternatively
through Fgf4-Fgfr2 signalling. Future experiments would be
essential in order to investigate further the mechanism by which
Sox2 regulates these or other signalling pathways to promote
trophectoderm induction in the preimplantation embryo. Further-
more, it has become apparent that Sox2 maternal transcripts and




This study was approved by the Ethics Review Committee of
the University of Manchester and the UK Home Office (Licence
Numbers 40/1939 and 40/2669).
Animals
Outbred female MF1 mice (Harlan Olac Ltd, Bicester, UK, as
used in our previous work) were crossed with male CD1 mice with
some preliminary data obtained from MF1xMF1 crosses. Mice
were kept under standard conditions (20–22uC, 40–60% humidity,
12 h light/dark cycle). Female mice were superovulated with 5 IU
of pregnant mare’s serum gonadotrophin (PMSG, Calbiochem) by
intraperitoneal injection (0.1 ml). Ovulation was synchronised by a
5 IU intraperitoneal injection (0.1 ml) of human chorionic
gonadotrophin (hCG, Intervet) 46–48 hours later. Female mice
were paired with males overnight and monitored the following
morning for the presence of a vaginal plug, which was designated
day 1 of pregnancy.
On day 2 female mice were killed by cervical dislocation,
oviducts were dissected and transferred into M2 medium (Sigma)
with 4 mg/ml bovine serum albumin (BSA, ICN Biomedical)
before flushing. Embryos were flushed using sterile M2/BSA and a
34-Gauge blunt-ended stainless steel needle (Coopers Needle-
works) attached to a 1 ml syringe.
Mouse embryo culture
Embryos were washed and cultured in a 30 ml drop of KSOM
(EmbryoMax, Chemicon), under embryo-tested mineral oil
(Sigma) at 37uC with 5% CO2 as described previously [58].
Mouse ES cell neural differentiation protocol
E14 mouse ES cells were cultured as described by Ying et al.
[88], in order to be induced to differentiate towards neuroecto-
dermal precursors. The medium was renewed every two days and
the cells were cultured for 14 days. They were then fixed and
immunostained as embryos, described below.
RNA interference (RNAi)
Specific oligonucleotide RNAi duplexes (Eurogentec) to Sox2
(NM_011443), Galanin (NM_010253) and Firefly Luciferase (FFL,
D25416, Photuris pennsylvanica luciferase) were designed, using the
Dharmacon short interference RNA (siRNA) oligo-designer-tool
(http://design.dharmacon.com/default.aspx), taking into account
8 criteria for siRNA specificity and efficiency, as determined by
Reynolds et al. [89]. Sequences were copied into the NCBI
BLAST database to confirm matching with the sequences of
interest. Sox2-duplex-1 was designed to target Sox2 sequence within
the HMG box, also found in other Sox genes; Sox2-duplexes -2 and
-3 were designed to target Sox2 sequences outside the conserved
region of the HMG box (both homologous to Sox2 only). Sense



























The 59-end of each sense oligo was conjugated to rhodamine.
30 ml of each sense and antisense oligo from the stock solutions
(100 mM) were mixed and 15 ml of annealing buffer (50 mM Tris/
pH 7.5, 100 mM NaCl, Eurogentec) was added. Oligos were
annealed by heating to 95uC for 2 minutes and then allowed to
cool for 1 hour at 4uC. The annealed duplex was diluted 1:20 in 4-
(2-hydroxyethyl)-1 piperazine ethanesulfonic acid (HEPES)-buff-
ered saline (HBS) supplemented with 4 mg/ml BSA to give a final
concentration of 2 mM (individual Sox2-siRNA duplexes and FFL-
siRNA duplex). Combination of the three Galanin-siRNA duplexes
created a final concentration of 6 mM.
Electroporation of mouse 2-cell embryos
Flushed 2-cell embryos were washed in HBS/BSA, transferred
into the electroporation microchamber slides (VWR) in a minimal
volume of medium and electroporated using an ECMH830
electroporator (VWR). Thirty embryos per group in 60 ml of each
annealed siRNA (50 mM) were loaded onto the electroporation
slides. The embryos were electroporated based on an assessment of
several voltages and times, the optimum conditions being those
used by Grabarek et al. [90]: 10 V voltage, 750 microseconds pulse
length, 6 pulses, 100 millisecond interval between pulses, unipolar
pulse. After electroporation the embryos were washed through
HBS/BSA and cultured up to day 5 (as above). Development was
Sox2 in the Early Embryo
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and 4 pm). At days 4 and 5 of culture some embryos were
harvested for RT-PCR, others stained by immunocytochemistry
or assessed for cell number and apoptosis by TUNEL assay.
Rescue experiments
Glycerol stocks of purified recombinant Sox2-TAT fusion
protein were generated as described previously [52]. The stocks
were freshly diluted 1:20 in KSOM media containing 0.5%
Albumax II (Invitrogen) yielding final Sox2-TAT concentrations
between 100 and 300 nM. Sox2-siRNA embryos were transferred
and cultured in the above supplemented media 24 h after RNAi.
Half the medium containing the Sox2-TAT protein was
replenished every 24 h and embryos were cultured up to day 5.
Rescue experiments were performed with Sox2-duplex-2 and Sox2-
duplex-3 siRNA embryos.
Immunostaining
Embryos were fixed in 4% paraformaldehyde (PFA, Sigma),
washed through PBS-Tween with 4 mg/ml BSA (PBS/BSA),
permeabilised with 1% Triton X-100 (Sigma) and washed through
PBS/BSA. In order to decrease background staining, embryos
were incubated for 10 min at room temperature in a solution of
2.6 mg/ml NH4Cl (Sigma) in PBS, and subsequently permeabi-
lised and washed as above. They were then immersed in 1:20
normal goat serum (NGS, Sigma) or normal donkey serum (NDS,
Sigma) before incubation in the appropriate dilution of the
primary antibody in PBS/BSA at 4uC overnight. They were then
washed and transferred into the appropriate secondary antibody
(Alexa-Fluor, Molecular Probes) at 1:200 dilution in PBS/BSA
and incubated for 1 hour in the dark at room temperature. After
washing, embryos were mounted in DAPI Vectashield mountant
(Vector Laboratories) and aspirated by capillary action into
0.2 mM diameter microcapillaries (Camlab), which were sealed
in both ends. Primary antibodies were as follows: Sox2 mouse
monoclonal (1:50, R&D), Sox2 rabbit polyclonal (1:500, Abcam),
Sox2 rabbit polyclonal (1:100, Chemicon), Oct4 mouse monoclo-
nal (1:250, BD Biosciences), Nanog goat IgG (1:10, R&D systems),
Yap rabbit polyclonal (1:25, Cell Signaling), Cdx2 rabbit
polyclonal (1:500, raised in rabbits to an N-terminal KLH-linked
peptide of mouse Cdx2 by Dr J. Collins, University of South-
ampton), Cdx2 mouse monoclonal IgG (1:400, Biogenex, gift from
Dr J. Draper, Toronto Hospital for Sick Children, Toronto),
Eomesodermin rabbit polyclonal (1:100, Orbigen), Fgfr2 mouse
IgG (1:100, Santa Cruz Biotechnology), Fgf4 goat polyclonal (1:50,
Santa Cruz Biotechnology), Occludin rabbit polyclonal (1:100,
Zymed), ZO1 mouse monoclonal IgG (1:100, Zymed), Desmo-
plakin mouse monoclonal IgG (1:10, gift from Prof. D. Garrod,
University of Manchester), E-cadherin rat monoclonal IgG (1:500,
Sigma), Gata4 goat IgG (1:200, Santa Cruz Biotechnology), Gata6
goat IgG (1:200, R&D). Irrelevant antibodies of the same species/
isotype as the primary antibodies replaced the primary antibodies,
as negative controls: rabbit IgG (Vector laboratories); mouse IgG
(Serotec); goat IgG (Santa Cruz Biotechnology); rat IgG (Santa
Cruz Biotechnology).
Confocal Microscopy
Embryos were viewed under a multi-photon scanning laser
confocal microscope (MRC 1024, BioRad) or a Leica (TCS Sp2
AOBS) inverted confocal microscope at the Bioimaging Facility,
University of Manchester. A Z-series of 2.5 mM optical sections
was collected and analysed using Confocal Assistant software
(version 4.02) or LCS Lite software.
Trypan Blue viability assay
In order to assess the lethality of the Sox2 siRNA phenotype, day
5 Sox2 siRNA embryos were incubated in Trypan Blue (Sigma)
solution, diluted 1:10 in KSOM embryo culture medium at room
temperature for 10 min before assessment by bright-field micros-
copy. Blue-stained cells were considered non-viable.
TUNEL Assay
Control and Sox2-siRNA embryos were assessed for apoptosis
using the TUNEL assay (Fluorescein conjugated In Situ Cell Death
Detection Kit,Roche)asinKamjoo et al.[58].Day4and5embryos
were fixed in4% PFA, permeabilised in0.5% Triton X-100, washed
in PBS/PVP, and incubated for 1 hour at 37uCi nt h ed a r ki n
TUNELsolution, a mixture ofterminal deoxynucleotidyltransferase
and fluorescein-conjugated dUTP in a ratio of 1:9. Positive control
embryos were incubated in DNase (Roche) for 20 minutes at 37uC
before TUNEL labelling. Negative control embryos were incubated
in fluorescein-conjugated dUTP only. After TUNEL-labelling,
embryos were washed in 0.5% Triton X-100 and PBS/PVP,
mounted with DAPI Vectashield and aspirated into microcapillary
tubes, which were then examined by confocal microscopy.
Assessment of apoptotic index and cell number
Apoptotic indices were calculated as number of apoptotic cells
divided by total number of cells (DAPI stained nuclei) per embryo.
Cell number per embryo was calculated by counting DAPI stained
nuclei in confocal images produced by a compressed Z-series of
2.5 mM optical sections for each embryo by means of Confocal
Assistant software (version 4.02).
Statistical Analysis
SPSS software (version 11.5) was used to perform Independent
Samples T-test for the apoptosis assessment. GraphPad Prism soft-
ware (version 4) was used for the chi-square tests to monitor dis-
tribution of embryos among preimplantation developmental stages.
RT-PCR
RNA was extracted from groups of 30 embryos by Dynabeads
mRNA Direct Micro Kit (Dynal). cDNA was synthesized using
Superscript II reverse transcriptase (Invitrogen) according to
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Forty-cycle PCR amplification was performed using thermal
cycler Mastercycler Gradient (Eppendorf). Amplicons, each
amplified from 50 ng cDNA, were run by electrophoresis
alongside a 100 bp DNA ladder (Invitrogen) or Hyperladder IV
(Bioline) on 2% agarose gels, at 100 V and 150 mA for 1 hour.
Mouse genomic DNA (Bioline) was used as positive control.
Sequencing
PCR product bands of the correct size were confirmed to contain
the expected gene product by DNA sequencing. Bands were excised
from the agarose gels and DNA extracted and purified using
QIAquick Gel-Extraction-Kit (QIAGEN) which were then se-
quenced (in the Sequencing Unit) using an ABI Prism 377 sequencer
(Applied Biosystems). Chromas software was used to read the base
compositions, which were copied into the NCBI BLAST database
(http://www.ncbi.nih.gov/BLAST/) to identify the sequences.
Western blotting
Validation of Sox2 antibody specificity was performed by
Western blotting using 2610
7 mouse ES cells (line R1)/ml of lysis
buffer(50 mMTris-Cl, 150 mMNaCl,0.02%Naazide,1%Triton
X-100) with 1 protease inhibitor cocktail tablet (Complete Mini,
Roche)/10 ml lysis buffer. A protein assay was performed using the
bicinchoninic acid (BCA) Kit (Pierce), following the Microplate
procedure, according to manufacturers’ instructions. Twenty five ml
lysates samples (50 mg of protein) were resolved by a 4–12%
NuPAGE Bis-Tris gel according to manufacturer’s recommenda-
tions (Invitrogen). 10 ml of BioRad kaleidoscope Multi-Coloured
Standard markers were run in parallel at 200 V, 110 mA for 50
minutes. Samples were transferred to a PVDF membrane
(Amersham Biosciences), which was blocked in 5% w/v dried milk
powder (Marvel) in 0.1% PBS-Tween, incubated with Sox2
antibody (1:1000, Abcam) in 5% w/v dried milk powder (Marvel)
at 4uC overnight and then with a peroxidase-labelled anti-rabbit
IgG (1:3000, DAKO) in 5% w/v dried milk powder (Marvel) for
1 hour. The enhanced chemiluminescence (ECL) detection system
(Amersham Biosciences) was used to visualize the protein bands.
Supporting Information
Figure S1 (A) Sox2 antibody positive controls: pluripotent mES
cells (Sox2-ES) stained for Sox2 (Abcam) in nuclei with some
cytoplasmic staining, as well as neurally differentiated E14 cells
(Sox2-N)withmainlynuclearSox2 proteinlocalisationandnegative
immunological controls (rabbit IgG isotype control and 2u Ab only
control) forSox2 embryostaining.Bars: 100mm.(B)Westernblot to
validatespecificityoftheSox2(Abcam)antibody;50mgmESprotein
loaded. Lane 1: 2o antibody only; 2: Sox2 (37kDa).
Found at: doi:10.1371/journal.pone.0013952.s001 (1.24 MB DOC)
Figure S2 Development of MF1xMF1 embryos after RNAi.
Sox2-duplex-1-siRNA embryos (hatched, N=30) were compared
with incubator-control (grey, N=20), FFL-siRNA (black, N=27)
and bench-control embryos (white, N=22). On day 5, while
control embryos formed blastocysts from 80% to 92.6%, only
3.3% of the Sox2-siRNA embryos formed blastocysts, with 96.7%
arresting at the morula stage. On day 5, chi-square tests revealed
significant differences (p,0.0001) between the % of Sox2-siRNA
morulae and all control morulae, as well as between the % of
Sox2-siRNA blastocysts and all control blastocysts.
Found at: doi:10.1371/journal.pone.0013952.s002 (0.22 MB DOC)
Figure S3 Immunostaining of day 4 and day 5 incubator ctrl
(untreated) and Sox2-duplex-3-siRNA embryos, with different
Sox2 (Chemicon) and Cdx2 (Biogenex) antibodies than the ones
presented in Figure 4. This confirms the expression pattern
described in Figures 3 and 4 for both markers, as well as absence of
Sox2 and Cdx2 proteins after Sox2 RNAi. The images are single
optical sections from confocal Z-series. At least 10 embryos were
stained for each antigen and representative embryos (not Sox2
siRNA ‘escapees’) are shown. Bars: 50 mm.
Found at: doi:10.1371/journal.pone.0013952.s003 (1.54 MB DOC)
Figure S4 RT-PCR for Sox2, Fgfr2, Fgf4, Cdx2, Eomes, Tead4,
Oct4, Nanog, Sox1, Sox3, Sox14, Sox15, Sox21 and Beta-actin
(40 cycles) on day 4: incubator-control embryos (lanes 1 and 3);
Sox2-duplex-1-siRNA embryos (lane 2); Sox2-duplex-3-siRNA
embryos (lane 4). In the absence of Sox2 transcripts after siRNA, a
clear reduction of Fgfr2, Ffg4, Cdx2, Eomes and Tead4 transcripts
in Sox2-siRNA embryos was observed. Oct4 and Nanog
transcripts were unaffected in Sox2 knock-down morulae com-
pared to incubator-control morulae. Sox1, Sox3, Sox14, Sox15
and Sox21 transcripts were not expressed in any of the control or
Sox2 knock-down morulae. Beta actin transcripts were detected in
all embryos.
Found at: doi:10.1371/journal.pone.0013952.s004 (0.70 MB DOC)
Figure S5 Immunofluorescence confirmation of transferred
Sox2 after initiation of the rescue experiment using the Sox2-
TAT protein. Sox2 siRNA R embryos were immunostained with
Sox2 6h, 12h and 18h after the first addition of Sox2-TAT
protein, to assess Sox2 protein recovery efficiency. Gradual
expression of Sox2 protein was confirmed, with signs of possible
endocytic uptake of the protein, as indicated by patchy expression
of Sox2.
Found at: doi:10.1371/journal.pone.0013952.s005 (1.07 MB DOC)
Figure S6 Immunological controls of embryo staining presented
in Figures 3 and 4; the upper panel (A to K) shows controls for
dual staining, the lower panel (L to S) illustrates controls for
staining with single antibodies. The images are single optical
sections from confocal Z-series. In all cases, the controls were
negative. A: anti-Sox2 1o + goat anti-mouse IgG (2o to Oct4,
Cdx2Biogenex, Fgfr2, ZO1, Desmoplakin); B: anti-Oct4 1o + goat
anti-rabbit IgG (2o to Sox2); C: anti-Cdx2Biogenex 1o + goat anti-
rabbit IgG (2o to Sox2); D: anti-Fgfr2 1o + goat anti-rabbit IgG
(2o to Sox2); E: anti-ZO1 1o + goat anti-rabbit IgG (2o to Sox2);
F: anti-Desmoplakin 1o + goat anti-rabbit IgG (2o to Sox2); G:
anti-Sox2 1o + donkey anti-goat IgG (2o to Nanog and Fgf4); H:
anti-Nanog 1o + donkey anti-rabbit IgG (2o to Sox2); I: anti-Fgf4
1o + donkey anti-rabbit IgG (2o to Sox2); J: anti-E-cadherin 1o +
goat anti-rabbit IgG (2o to Sox2); K: anti-Sox2 1o + goat anti-rat
IgG (2o to E-cadherin); L: Rabbit IgG isotype control to Sox2,
Cdx2Jane Collins, Eomes, Occludin 1o antibodies; M: Mouse IgG
isotype control to Oct4, Cdx2Biogenex, Fgfr2, ZO1, Desmoplakin
1o antibodies; N: Goat IgG isotype control to Nanog, Fgf4 1o
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P: Goat anti-rabbit IgG 2o antibody only control to Sox2,
Cdx2Jane Collins, Eomes, Occludin; Q: Goat anti-mouse IgG 2o
antibody only control to Oct4, Cdx2Biogenex, Fgfr2, ZO1,
Desmoplakin; R: Donkey anti-goat IgG 2o antibody only control
to Nanog, Fgf4; S: Goat anti-rat IgM 2o antibody only control to
E-cadherin; T: Goat anti-rabbit IgG 2o antibody only control to
Yap; U: Donkey anti-goat IgG 2o antibody only control to Gata4,
Gata6; V: Goat IgG isotype control to Gata4, Gata6. Bars: 50 mm.
Found at: doi:10.1371/journal.pone.0013952.s006 (1.16 MB DOC)
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